Lytix Biopharma AS
Clinical-stage immuno-oncology company developing oncolytic molecules for cancer.
LYTIX | OL
Overview
Corporate Details
- ISIN(s):
- NO0010405780
- LEI:
- 549300NXMIMRSBCDZO71
- Country:
- Norway
- Address:
- Sandakerveien 138, 0484 OSLO
- Website:
- https://www.lytixbiopharma.com/
- Sector:
- Manufacturing
Description
Lytix Biopharma AS is a clinical-stage immuno-oncology company that develops a proprietary platform of oncolytic molecules for cancer treatment. The company's technology is based on molecules designed to selectively target and lyse cancer cell membranes. This process releases a broad spectrum of tumor antigens, which in turn stimulates a patient's immune system to recognize and attack the cancer, effectively turning immunologically "cold" tumors "hot". Its lead drug candidate, ruxotemitide, is being evaluated in clinical trials as a neoadjuvant treatment for various solid tumors, including melanoma and basal cell carcinoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-11 13:39 |
LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - Attac…
|
English | 66.4 KB | ||
| 2025-12-11 13:39 |
LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER
|
English | 1.6 KB | ||
| 2025-11-14 07:00 |
Lytix Biopharma: Invitation to Q3 2025 Results Presentation - Attachment: Lytix…
|
Norwegian | 612.2 KB | ||
| 2025-11-14 07:00 |
Lytix Biopharma: Invitation to Q3 2025 Results Presentation
|
English | 2.0 KB | ||
| 2025-11-11 07:00 |
Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Me…
|
English | 641.5 KB | ||
| 2025-11-11 07:00 |
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhosp…
|
Norwegian | 170.6 KB | ||
| 2025-11-11 07:00 |
Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Me…
|
English | 5.5 KB | ||
| 2025-11-11 07:00 |
Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhosp…
|
Norwegian | 4.8 KB | ||
| 2025-11-10 07:00 |
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 F…
|
English | 1.2 MB | ||
| 2025-11-10 07:00 |
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 F…
|
English | 634.6 KB | ||
| 2025-11-10 07:00 |
New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 F…
|
English | 4.2 KB | ||
| 2025-10-10 11:46 |
Financial calendar
|
English | 430 bytes | ||
| 2025-10-10 11:46 |
Finansiell kalender
|
Norwegian | 417 bytes | ||
| 2025-10-08 07:00 |
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data f…
|
English | 646.0 KB | ||
| 2025-10-08 07:00 |
Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data f…
|
English | 3.6 KB |
Automate Your Workflow. Get a real-time feed of all Lytix Biopharma AS filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lytix Biopharma AS
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lytix Biopharma AS via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
